Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes

Thrombosis Research

Volumn 120, Issue 6, 2007, Pages 811-814

  Weber, Michael ^a   Rabenau, Birgitt ^a   Stanisch, Michael ^a   Nef, Holger M ^a   Möllmann, Helge ^a   Elsässer, Albrecht ^a   Mitrovic, Vesselin ^a   Heeschen, Christopher ^b   Hamm, Christian ^a  

^a KERCKHOFF HEART CENTER   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CLOPIDOGREL; EDETIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; CD40 LIGAND; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SOLUBILITY;

EID: 34347378387     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.01.014     Document Type: Article

References (10)

1. Schonbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58 (2001) 4-43
2. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
3. Henn V., Steinbach S., Buchner K., Presek P., and Kroczek R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98 (2001) 1047-1054
4. Urbich C., Dernbach E., Aicher A., Zeiher A.M., and Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106 (2002) 981-986
5. Aukrust P., Muller F., Ueland T., Berget T., Aaser E., Brunsvig A., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 (1999) 614-620
6. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
7. Varo N., de Lemos J.A., Libby P., Morrow D.A., Murphy S.A., Nuzzo R., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
8. Weber M., Rabenau B., Stanisch M., Elsaesser A., Mitrovic V., Heeschen C., et al. Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 52 (2006) 888-891
9. Ahn E.R., Lander G., Jy W., Bidot C.J., Jimenez J.J., Horstman L.L., et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114 (2004) 143-148
10. Halldorsdottir A.M., Stoker J., Porche-Sorbet R., and Eby C.S. Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method. Clin Chem 51 (2005) 1054-1057